Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer
Semaglutide the original ~14.9% average body-weight reduction at 52 weeks Targets GLP-1 (one pathway) Weekly injection Best for: first-timers, or anyone sensitive to side effects Tirzepatide the upgrade ~22.1% average body-weight reduction at 52 weeks Targets GLP-1 + GIP (two pathways) Weekly injection Best for: plateaued on semaglutide, or want stronger results Retatrutide the newest ~25.9% average body-weight reduction at 52 weeks Targets GLP-1 + GIP + glucagon (three pathways) Weekly injection Best for: want the newest science, comfortable with a compounded option Semaglutide: the original Semaglutide is a GLP-1 receptor agonist
J Clin Endocrinol Metab 107(6):e2590e2599
Int J Endocrinol, 2014
US$ 26.45
US$ 28.29
US$ 24.39
US$ 21.62
US$ 25.94
US$ 26.29
US$ 24.96
